Fisetin Promotes Autophagy in Osteosarcoma by Activating the ROS / FOXO3 Axis via Oxidative Stress
Phytotherapy Research · 2026-07 · 40 (7) · 4384-4403
DOI: 10.1002/ptr.70347 ↗Kurz gefasst
Fachartikel in der Zeitschrift Phytotherapy Research, online erschienen am 07.05.2026. Verfasst von Yujie Hu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Osteosarcoma, Forkhead Box Protein O3, Flavonols, Autophagy. Die Arbeit nennt 44 Literaturangaben. Gefördert von: Pudong New Area Health and Family Planning Commission Health Research Project, Pudong New Area Science and Technology Development Fund Livelihood Research Special Project, Shanghai Medical College of Health Sciences 2025 University Research Fund Project.
Abstract (Originalsprache)
Osteosarcoma is a malignant bone tumor that occurs in adolescents and for which surgical resection and chemotherapy are the treatments of first choice. However, tumor cell metastasis and the toxic effects of chemotherapeutic agents bring great challenges to the treatment of osteosarcoma. Fisetin, a dietary flavonoid derived from vegetables and fruits, plays a therapeutic role in many cancers, but its role and underlying mechanism on osteosarcoma remain unrevealed. This study found that fisetin significantly inhibited the proliferation of osteosarcoma cells and organoids. RNA sequencing revealed that forkhead box O3 (FOXO3) may be a key target of fisetin in its anti‐osteosarcoma activity, which was also verified by immunofluorescence. siFOXO3 reversed the effects of fisetin on proliferation, apoptosis, and migration of osteosarcoma cells. Fisetin exerts its effects by targeting the ROS/FOXO3 pathway to promote the binding of FOXO3 to the microtubule‐associated protein light chain 3 (LC3) promoter, thereby upregulating LC3 levels and inducing autophagy. Subsequently, activated autophagy further triggers ferroptosis, while silencing LC3 reversed fisetin‐induced ferroptosis. In vivo, fisetin inhibited tumor growth while promoting FOXO3 and LC3, and inhibiting SLC7A11 protein expression. Therefore, fisetin‐induced autophagy in osteosarcoma cells may be associated with the reactive oxygen species (ROS)/FOXO3 axis, thereby promoting ferroptosis. These findings highlight fisetin's potential as a unique therapy for osteosarcoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Pharmacy, Huashan Hospital, Fudan University, Shanghai, China.
- School of Pharmacy, Shanghai Jiao Tong University, Shanghai, China.
ORCID-Profile: Yujie Hu, Lanyi Wei, Quanjun Yang, Yonglong Han
Förderung
- Pudong New Area Health and Family Planning Commission Health Research Project
- Pudong New Area Science and Technology Development Fund Livelihood Research Special Project
- Shanghai Medical College of Health Sciences 2025 University Research Fund Project
Zitieren
APA
Hu, Y., Wei, L., Meng, J., Xiang, D., Zhang, X., Zhang, J., Yang, Q., Zhou, Y., Xu, L., Wang, M., Chen, J., & Han, Y. (2026). Fisetin Promotes Autophagy in Osteosarcoma by Activating the ROS / FOXO3 Axis via Oxidative Stress. Phytotherapy Research, 40(7), 4384-4403. https://doi.org/10.1002/ptr.70347
Vancouver
Hu Y, Wei L, Meng J, Xiang D, Zhang X, Zhang J, et al. Fisetin Promotes Autophagy in Osteosarcoma by Activating the ROS / FOXO3 Axis via Oxidative Stress. Phytotherapy Research. 2026;40(7):4384-4403. doi:10.1002/ptr.70347
BibTeX
@article{Hu2026,
author = {Hu, Yujie and Wei, Lanyi and Meng, Jingjing and Xiang, Danfeng and Zhang, Xiangqi and Zhang, Jingxian and Yang, Quanjun and Zhou, Yangyun and Xu, Lingyan and Wang, Mengyue and Chen, Junjun and Han, Yonglong},
title = {Fisetin Promotes Autophagy in Osteosarcoma by Activating the ROS / FOXO3 Axis via Oxidative Stress},
journal = {Phytotherapy Research},
year = {2026},
volume = {40},
number = {7},
pages = {4384--4403},
doi = {10.1002/ptr.70347}
}
EUVIMED